Targeting the interleukin-6/jak/stat pathway in human malignancies

Journal of Clinical Oncology

Volumn 30, Issue 9, 2012, Pages 1005-1014

  Sansone, Pasquale ^a   Bromberg, Jacqueline ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; GLYCOPROTEIN GP 130; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE 2; LESTAURTINIB; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PYRIMETHAMINE; RUXOLITINIB; SARILUMAB; SILTUXIMAB; SIRUKUMAB; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; THROMBOPOIETIN RECEPTOR; TOCILIZUMAB; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; XL 019; ANTINEOPLASTIC AGENT; STAT PROTEIN;

ADENOMA; ANEMIA; B CELL LEUKEMIA; BREAST CANCER; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DISEASE CONTROL; DISEASE COURSE; ENZYME ACTIVATION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; LEUKEMIA; LIVER CELL CARCINOMA; LUPUS VULGARIS; METASTASIS; MULTIPLE MYELOMA; MYELOFIBROSIS; MYELOMA; MYELOPROLIFERATIVE DISORDER; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TUMOR CELL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; INTERLEUKIN-6; JANUS KINASES; NEOPLASMS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84860630975     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.8907     Document Type: Review

References (185)

1. Darnell JE Jr: STATs and gene regulation. Science 277:1630-1635, 1997
2. Darnell JE Jr: Transcription factors as targets for cancer therapy. Nat Rev Cancer 2:740-749, 2002
3. Jove R: Preface: Stat signaling. Oncogene 19:2466-2467, 2000
4. Mertens C, Darnell JE Jr: SnapShot: JAK-STAT signaling. Cell 131:612, 2007
5. Kramer OH, Heinzel T: Phosphorylation-acetylation switch in the regulation of STAT1 signaling. Mol Cell Endocrinol 315:40-48, 2010
6. Maiti NR, Sharma P, Harbor PC, et al: Serine phosphorylation of Stat6 negatively controls its DNA-binding function. J Interferon Cytokine Res 25:553-563, 2005 (Pubitemid 41395843)
7. Morinobu A, Gadina M, Strober W, et al: STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. Proc Natl Acad Sci U S A 99:12281-12286, 2002
8. Xue HH, Fink DW Jr, Zhang X, et al: Serine phosphorylation of Stat5 proteins in lymphocytes stimulated with IL-2. Int Immunol 14:1263-1271, 2002 (Pubitemid 35331423)
9. Vanhatupa S, Ungureanu D, Paakkunainen M, et al: MAPK-induced Ser727 phosphorylation promotes SUMOylation of STAT1. Biochem J 409:179-185, 2008
10. Friedbichler K, Kerenyi MA, Kovacic B, et al: Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood 116:1548-1558, 2010
11. Decker T, Kovarik P: Serine phosphorylation of STATs. Oncogene 19:2628-2637, 2000 (Pubitemid 30339219)
12. Lee JL, Wang MJ, Chen JY: Acetylation and activation of STAT3 mediated by nuclear translocation of CD44. J Cell Biol 185:949-957, 2009
13. Sun Y, Chin YE, Weisiger E, et al: Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J Immunol 182:5899-5903, 2009
14. Ray S, Lee C, Hou T, et al: Requirement of histone deacetylase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) nucleocytoplasmic distribution. Nucleic Acids Res 36:4510-4520, 2008
15. Yuan ZL, Guan YJ, Chatterjee D, et al: Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307:269-273, 2005 (Pubitemid 40116244)
16. O'Shea JJ, Kanno Y, Chen X, et al: Cell signaling: Stat acetylation - A key facet of cytokine signaling? Science 307:217-218, 2005 (Pubitemid 40116227)
17. Kramer OH, Baus D, Knauer SK, et al: Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev 20:473-485, 2006 (Pubitemid 43244401)
18. Komyod W, Bauer UM, Heinrich PC, et al: Are STATS arginine-methylated? J Biol Chem 280: 21700-21705, 2005 (Pubitemid 40834298)
19. Lee H, Herrmann A, Deng JH, et al: Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15:283-293, 2009
20. Hou T, Ray S, Lee C, et al: The STAT3 NH2-terminal domain stabilizes enhanceosome assembly by interacting with the p300 bromodomain. J Biol Chem 283:30725-30734, 2008
21. Sun W, Snyder M, Levy DE, et al: Regulation of Stat3 transcriptional activity by the conserved LPMSP motif for OSM and IL-6 signaling. FEBS Lett 580:5880-5884, 2006 (Pubitemid 44584288)
22. Ulane CM, Rodriguez JJ, Parisien JP, et al: STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling. J Virol 77:6385-6393, 2003 (Pubitemid 36588409)
23. Alexander WS, Hilton DJ: The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 22:503-529, 2004 (Pubitemid 38680432)
24. Kishimoto T: Interleukin-6: From basic science to medicine - 40 years in immunology. Annu Rev Immunol 23:1-21, 2005
25. Nishimoto N, Kishimoto T: Interleukin 6: From bench to bedside. Nat Clin Pract Rheumatol 2:619-626, 2006 (Pubitemid 44650950)
26. Xu D, Qu CK: Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci 13:4925-4932, 2008 (Pubitemid 351599646)
27. Shuai K, Liu B: Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3:900-911, 2003 (Pubitemid 37411719)
28. ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, et al: Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 22:5662-5668, 2002 (Pubitemid 34815816)
29. Veeriah S, Brennan C, Meng S, et al: The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A 106:9435-9440, 2009
30. Shuai K, Liu B: Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol 5:593-605, 2005 (Pubitemid 41113191)
31. Chung CD, Liao J, Liu B, et al: Specific inhibition of Stat3 signal transduction by PIAS3. Science 278:1803-1805, 1997 (Pubitemid 27527648)
32. Levy DE: Physiological significance of STAT proteins: Investigations through gene disruption in vivo. Cell Mol Life Sci 55:1559-1567, 1999 (Pubitemid 29445821)
33. Schindler C, Levy DE, Decker T: JAK-STAT signaling: From interferons to cytokines. J Biol Chem 282:20059-20063, 2007 (Pubitemid 47099977)
34. Decker T, Muller M, Stockinger S: The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol 5:675-687, 2005 (Pubitemid 43086170)
35. Levy DE, Darnell JE Jr: Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 3:651-662, 2002 (Pubitemid 34987786)
36. Griffiths DS, Li J, Dawson MA, et al: LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell Biol 13:13-21, 2010
37. Rui L, Emre NC, Kruhlak MJ, et al: Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 18:590-605, 2010
38. Liu F, Zhao X, Perna F, et al: JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 19:283-294, 2011
39. Caretto D, Katzman SD, Villarino AV, et al: Cutting edge: The Th1 response inhibits the generation of peripheral regulatory T cells. J Immunol 184:30-34, 2010
40. Ma H, Lu C, Ziegler J, et al: Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. J Clin Invest 121:2554-2569, 2011
41. Liu L, Okada S, Kong XF, et al: Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 208:1635-1648, 2011
42. Shao H, Cheng HY, Cook RG, et al: Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 63:3923-3930, 2003 (Pubitemid 36917907)
43. Zhang T, Ma J, Cao X: Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling. Biochem J 376:457-464, 2003 (Pubitemid 38010531)
44. Xia L, Wang L, Chung AS, et al: Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J Biol Chem 277:30716-30723, 2002 (Pubitemid 34970768)
45. Boccaccio C, Andò M, Tamagnone L, et al: Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391:285-288, 1998
46. Kermorgant S, Parker PJ: Receptor trafficking controls weak signal delivery: A strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol 182:855-863, 2008
47. Carlesso N, Frank DA, Griffin JD: Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 183:811-820, 1996 (Pubitemid 26113953)
48. Ilaria RL Jr, Van Etten RA: P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271:31704-31710, 1996
49. Shuai K, Halpern J, ten Hoeve J, et al: Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13:247-254, 1996 (Pubitemid 26334856)
50. Yu CL, Meyer DJ, Campbell GS, et al: Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269:81-83, 1995
51. Bromberg J, Wang TC: Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 15:79-80, 2009
52. Grivennikov S, Karin M: Autocrine IL-6 signaling: A key event in tumorigenesis? Cancer Cell 13:7-9, 2008 (Pubitemid 350309747)
53. Kato T: Stat3-driven cancer-related inflammation as a key therapeutic target for cancer immunotherapy. Immunotherapy 3:587-590, 2010
54. Chen Z, O'Shea JJ: Th17 cells: A new fate for differentiating helper T cells. Immunol Res 41:87-102, 2008
55. Korn T, Bettelli E, Oukka M, et al: IL-17 and Th17 cells. Annu Rev Immunol 27:485-517, 2009
56. Kujawski M, Zhang C, Herrmann A, et al: Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res 70:9599-9610, 2010
57. Grivennikov S, Karin E, Terzic J, et al: IL-6 and stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103-113, 2009
58. Kortylewski M, Kujawski M, Herrmann A, et al: Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res 69: 2497-2505, 2009
59. Kortylewski M, Swiderski P, Herrmann A, et al: In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 27:925-932, 2009
60. Zhang M, Liu Q, Mi S, et al: Both miR-17-5p and miR-20a alleviate suppressive potential of myeloid-derived suppressor cells by modulating STAT3 expression. J Immunol 186:4716-4724, 2011
61. Littman DR, Rudensky AY: Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140:845-858, 2010
62. Stewart CA, Trinchieri G: At 17, in-10's passion need not inflame. Immunity 34:460-462, 2011
63. Stewart CA, Trinchieri G: Reinforcing suppression using regulators: A new link between STAT3, IL-23, and Tregs in tumor immunosuppression. Cancer Cell 15:81-83, 2009
64. Huber S, Gagliani N, Esplugues E, et al: Th17 cells express interleukin-10 receptor and are controlled by Foxp3 and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity 34:554-565, 2011
65. Chaudhry A, Samstein RM, Treuting P, et al: Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34:566-578, 2011
66. Reindl W, Weiss S, Lehr HA, et al: Essential crosstalk between myeloid and lymphoid cells for development of chronic colitis in myeloid-specific signal transducer and activator of transcription 3-deficient mice. Immunology 120:19-27, 2007 (Pubitemid 44950466)
67. Takeda K, Clausen BE, Kaisho T, et al: Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10:39-49, 1999 (Pubitemid 29077382)
68. Murai M, Turovskaya O, Kim G, et al: Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 10:1178-1184, 2009
69. Smith AM, Qualls JE, O'Brien K, et al: A distal enhancer in Il12b is the target of transcriptional repression by the STAT3 pathway and requires the B-ZIP protein NFIL-3. J Biol Chem 286: 23582-23590, 2011
70. Zhang H, Nguyen-Jackson H, Panopoulos AD, et al: STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood 116:2462-2471, 2010
71. Horiguchi N, Lafdil F, Miller AM, et al: Dissociation between liver inflammation and hepatocellular damage induced by carbon tetrachloride in myeloid cell-specific signal transducer and activator of transcription 3 gene knockout mice. Hepatology 51:1724-1734, 2010
72. Avery DT, Deenick EK, Ma CS, et al: B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med 207:155-171, 2010
73. Minegishi Y: Hyper-IgE syndrome. Curr Opin Immunol 21:487-492, 2009
74. Saito M, Nagasawa M, Takada H, et al: Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. J Exp Med 208:235-249, 2011
75. Milner JD, Brenchley JM, Laurence A, et al: Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452:773-776, 2008 (Pubitemid 351521078)
76. Holland SM, DeLeo FR, Elloumi HZ, et al: STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 357:1608-1619, 2007 (Pubitemid 47598403)
77. Minegishi Y, Saito M, Tsuchiya S, et al: Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448:1058-1062, 2007 (Pubitemid 47345590)
78. Kumanovics A, Perkins SL, Gilbert H, et al: Diffuse large B cell lymphoma in hyper-IgE syndrome due to STAT3 mutation. J Clin Immunol 30:886-893, 2010
79. Bowman T, Garcia R, Turkson J, et al: STATs in oncogenesis. Oncogene 19:2474-2488, 2000 (Pubitemid 30339203)
80. Calò V, Migliavacca M, Bazan V, et al: STAT proteins: From normal control of cellular events to tumorigenesis. J Cell Physiol 197:157-168, 2003 (Pubitemid 37485244)
81. Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9:798-809, 2009
82. Sriuranpong V, Park JI, Amornphimoltham P, et al: Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 63:2948-2956, 2003 (Pubitemid 36667168)
83. Levine RL, Gilliland DG: Myeloproliferative disorders. Blood 112:2190-2198, 2008
84. Yoshikawa H, Matsubara K, Qian GS, et al: SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth- suppression activity. Nat Genet 28:29-35, 2001 (Pubitemid 32405812)
85. He B, You L, Uematsu K, et al: SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A 100:14133-14138, 2003 (Pubitemid 37499203)
86. Meenhuis A, Irandoust M, Wölfler A, et al: Janus kinases promote cell-surface expression and provoke autonomous signalling from routing-defective G-CSF receptors. Biochem J 417:737-746, 2009
87. Scott LM: The JAK2 exon 12 mutations: A comprehensive review. Am J Hematol 86:668-676, 2011
88. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790, 2005 (Pubitemid 40570926)
89. Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397, 2005 (Pubitemid 40544655)
90. Pikman Y, Lee BH, Mercher T, et al: MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270, 2006
91. Koppikar P, Abdel-Wahab O, Hedvat C, et al: Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 115:2919-2927, 2010
92. Rebouissou S, Amessou M, Couchy G, et al: Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457:200-204, 2009
93. Bersenev A, Wu C, Balcerek J, et al: Lnk constrains myeloproliferative diseases in mice. J Clin Invest 120:2058-2069, 2010
94. Oh ST, Simonds EF, Jones C, et al: Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116:988-992, 2010
95. Lee H, Deng J, Kujawski M, et al: STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 16:1421-1428, 2010
96. Yang J, Liao X, Agarwal MK, et al: Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev 21:1396-1408, 2007 (Pubitemid 46871042)
97. Ichiba M, Nakajima K, Yamanaka Y, et al: Autoregulation of the Stat3 gene through cooperation with a cAMP-responsive element-binding protein. J Biol Chem 273:6132-6138, 1998 (Pubitemid 28144693)
98. Ancrile B, Lim KH, Counter CM: Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 21:1714-1719, 2007 (Pubitemid 47076470)
99. Gao SP, Mark KG, Leslie K, et al: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117:3846-3856, 2007 (Pubitemid 350224094)
100. Sansone P, Storci G, Tavolari S, et al: IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117:3988-4002, 2007 (Pubitemid 350224108)
101. Levy DE, Inghirami G: STAT3: A multifaceted oncogene. Proc Natl Acad Sci U S A 103:10151-10152, 2006 (Pubitemid 44051135)
102. Ara T, Declerck YA: Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 46:1223-1231, 2010
103. Kortylewski M, Yu H: Stat3 as a potential target for cancer immunotherapy. J Immunother 30:131-139, 2007 (Pubitemid 46667794)
104. Fletcher S, Drewry JA, Shahani VM, et al: Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem Cell Biol 87:825-833, 2009
105. Chan KS, Sano S, Kiguchi K, et al: Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 114:720-728, 2004 (Pubitemid 39578762)
106. Chiarle R, Simmons WJ, Cai H, et al: Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11:623-629, 2005 (Pubitemid 40868302)
107. Bollrath J, Phesse TJ, von Burstin VA, et al: Gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15:91-102, 2009
108. Ranger JJ, Levy DE, Shahalizadeh S, et al: Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. Cancer Res 69:6823-6830, 2009
109. Musteanu M, Blaas L, Mair M, et al: Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology 138:1003-1011, 2010; e1-e5
110. Jenkins BJ, Grail D, Nheu T, et al: Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med 11:845-852, 2005 (Pubitemid 41161116)
111. Jenkins BJ, Roberts AW, Greenhill CJ, et al: Pathological consequences of STAT3 hyper-activation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. Blood 109:2380-2388, 2006 (Pubitemid 46425878)
112. Judd LM, Bredin K, Kalantzis A, et al: STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis. Gastroenterology 131:1073-1085, 2006 (Pubitemid 44498694)
113. Li Y, Du H, Qin Y, et al: Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res 67:8494-8503, 2007 (Pubitemid 47437423)
114. Hedvat M, Huszar D, Herrmann A, et al: The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16:487-497, 2009
115. Ling X, Arlinghaus RB: Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 65:2532-2536, 2005 (Pubitemid 40490046)
116. Corcoran RB, Contino G, Deshpande V, et al: STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis. Cancer Res 71:5020-5029, 2011
117. Fukuda A, Wang SC, Morris JP 4th, et al: Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19:441-455, 2011
118. Lesina M, Kurkowski MU, Ludes K, et al: Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19:456-469, 2011
119. He G, Karin M: NF-kappaB and STAT3: Key players in liver inflammation and cancer. Cell Res 21:159-168, 2011
120. Li N, Grivennikov SI, Karin M: The unholy trinity: Inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 19:429-431, 2011
121. Park EJ, Lee JH, Yu GY, et al: Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140:197-208, 2010
122. Tartour E, Pere H, Maillere B, et al: Angiogenesis and immunity: A bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 30:83-95, 2011
123. Poschke I, Mougiakakos D, Hansson J, et al: Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 70: 4335-4345, 2010
124. Herrmann A, Kortylewski M, Kujawski M, et al: Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res 70: 7455-7464, 2010
125. Studebaker AW, Storci G, Werbeck JL, et al: Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 68:9087-9095, 2008
126. Karnoub AE, Dash AB, Vo AP, et al: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557-563, 2007 (Pubitemid 47525152)
127. Koppikar P, Lui VW, Man D, et al: Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clin Cancer Res 14:7682-7690, 2008
128. Lai SY, Childs EE, Xi S, et al: Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 24:4442-4449, 2005 (Pubitemid 40961767)
129. Xi S, Zhang Q, Gooding WE, et al: Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res 63:6763-6771, 2003 (Pubitemid 37322957)
130. Dolled-Filhart M, Camp RL, Kowalski DP, et al: Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 9:594-600, 2003 (Pubitemid 36182589)
131. Diaz N, Minton S, Cox C, et al: Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 12:20-28, 2006 (Pubitemid 43166171)
132. Berishaj M, Gao SP, Ahmed S, et al: Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 9:R32, 2007
133. Marotta LL, Almendro V, Marusyk A, et al: The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors. J Clin Invest 121:2723-2735, 2011
134. Nevalainen MT, Xie J, Torhorst J, et al: Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 22:2053-2060, 2004 (Pubitemid 41095137)
135. Yamashita H, Nishio M, Ando Y, et al: Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer 13:885-893, 2006 (Pubitemid 44763264)
136. Walker SR, Nelson EA, Zou L, et al: Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res 7:966-976, 2009
137. Tran TH, Utama FE, Lin J, et al: Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism. Cancer Res 70:1711-1721, 2010
138. Culig Z: Cytokine disbalance in common human cancers. Biochim Biochim Biophys Acta 1813:308-314, 2011
139. Wallner L, Dai J, Escara-Wilke J, et al: Inhibition of interleukin-6 with CNTO328, an antiinterleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 66:3087-3095, 2006
140. Dorff TB, Goldman B, Pinski JK, et al: Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 16:3028-3034, 2010
141. Puchalski T, Prabhakar U, Jiao Q, et al: Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 16:1652-1661, 2010
142. Nakashima Y, Kondo M, Harada H, et al: Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: Tocilizumab in combination with methotrexate. Mod Rheumatol 20:343-352, 2010
143. Garnero P, Thompson E, Woodworth T, et al: Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 62:33-43, 2010
144. Meydan N, Grunberger T, Dadi H, et al: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379:645-648, 1996 (Pubitemid 26053453)
145. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al: Signal transducer and activator of transcription-3, inflammation, and cancer: How intimate is the relationship? Ann N Y Acad Sci 1171:59-76, 2009
146. Wernig G, Kharas MG, Okabe R, et al: Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13:311-320, 2008 (Pubitemid 351446195)
147. Quintás-Cardama A, Vaddi K, Liu P, et al: Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: Therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115:3109-3117, 2010
148. Verstovsek S: Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program 636-642, 2009
149. Sen M, Tosca PJ, Zwayer C, et al: Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol 63:983-995, 2009
150. Boehm AL, Sen M, Seethala R, et al: Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol 73:1632-1642, 2008 (Pubitemid 351724352)
151. Lui VW, Boehm AL, Koppikar P, et al: Anti-proliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: The role of STAT1. Mol Pharmacol 71:1435-1443, 2007 (Pubitemid 46658696)
152. Xi S, Gooding WE, Grandis JR: In vivo anti-tumor efficacy of STAT3 blockade using a transcription factor decoy approach: Implications for cancer therapy. Oncogene 24:970-979, 2005 (Pubitemid 40313874)
153. Leong PL, Andrews GA, Johnson DE, et al: Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A 100:4138-4143, 2003 (Pubitemid 36418170)
154. Zhao W, Jaganathan S, Turkson J: A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro. J Biol Chem 285:35855-35865, 2010
155. Zhang X, Yue P, Fletcher S, et al: A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol 79:1398-1409, 2010
156. Redell MS, Ruiz MJ, Alonzo TA, et al: Stat3 signaling in acute myeloid leukemia: Liganddependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 117:5701-5709, 2011
157. Madoux F, Koenig M, Sessions H, et al: Modulators of STAT transcription factors for the targeted therapy of cancer (STAT3 inhibitors). Bethesda, MD, National Center for Biotechnology Information, 2011
158. Nelson EA, Sharma SV, Settleman J, et al: A chemical biology approach to developing STAT inhibitors: Molecular strategies for accelerating clinical translation. Oncotarget 2:518-524, 2011
159. Nelson EA, Walker SR, Weisberg E, et al: The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 117:3421-3429, 2011
160. Nelson EA, Walker SR, Kepich A, et al: Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 112:5095-5102, 2008
161. Li WX: Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol 18:545-551, 2008
162. Regis G, Pensa S, Boselli D, et al: Ups and downs: The STAT1:STAT3 seesaw of interferon and gp130 receptor signalling. Semin Cell Dev Biol 19: 351-359, 2008
163. Yang J, Chatterjee-Kishore M, Staugaitis SM, et al: Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 65:939-947, 2005 (Pubitemid 40216455)
164. Kumar A, Commane M, Flickinger TW, et al: Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 278:1630-1632, 1997 (Pubitemid 27516283)
165. Zhang Q, Wang HY, Marzec M, et al: STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci U S A 102:6948-6953, 2005 (Pubitemid 40675422)
166. Zhang Q, Wang HY, Liu X, et al: STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nat Med 13:1341-1348, 2007 (Pubitemid 350073594)
167. Silver DL, Naora H, Liu J, et al: Activated signal transducer and activator of transcription (STAT) 3: Localization in focal adhesions and
168. Gough DJ, Corlett A, Schlessinger K, et al: Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324:1713-1716, 2009
169. Reich NC: STAT3 revs up the powerhouse. Sci Signal 2:pe61, 2009
170. Ng DC, Lin BH, Lim CP, et al: Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol 172:245-257, 2006 (Pubitemid 43112971)
171. Walker SR, Chaudhury M, Nelson EA, et al: Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling. Mol Pharmacol 78:903-908, 2010
172. Hazan-Halevy I, Harris D, Liu Z, et al: STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood 115:2852-2863, 2010
173. Kortylewski M, Xin H, Kujawski M, et al: Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15:114-123, 2009
174. Olkhanud PB, Damdinsuren B, Bodogai M, et al: Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4 T cells to T-regulatory cells. Cancer Res 71:3505-3515, 2011
175. Betts BC, Abdel-Wahab O, Curran SA, et al: Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells, yet preserves immunity to recall antigen. Blood 118:5330-5339, 2011
176. Betts BC, St Angelo ET, Kennedy M, et al: Anti-IL-6 receptor alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses. Blood 118:5340-5343, 2011
177. Xin H, Herrmann A, Reckamp K, et al: Antiangiogenic and anti-metastatic activity of JAK inhibitor AZD1480. Cancer Res 71:6601-6610, 2011
178. Chen CD, Welsbie DS, Tran C, et al: Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39, 2004 (Pubitemid 38524696)
179. De Miguel F, Lee SO, Onate SA, et al: Stat3 enhances transactivation of steroid hormone receptors. Nucl Recept 1:3, 2003
180. Barton BE, Karras JG, Murphy TF, et al: Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 3:11-20, 2004 (Pubitemid 39193674)
181. Aaronson DS, Muller M, Neves SR, et al: An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells. Mol Cell Endocrinol 270:50-56, 2007 (Pubitemid 46670550)
182. de la Iglesia N, Konopka G, Lim KL, et al: Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J Neurosci 28:5870-5878, 2008
183. de la Iglesia N, Konopka G, Puram SV, et al: Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 22:449-462, 2008 (Pubitemid 351272753)
184. Morris PG, McArthur HL, Hudis C, et al: Dose-dense chemotherapy for breast cancer: What does the future hold? Future Oncol 6:951-965, 2010
185. Clarke JL, Pao W, Wu N, et al: High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99:283-286, 2010